Wells Fargo analyst Eva Fortea Verdejo raised the firm’s price target on Kiniksa to $35 from $34 and keeps an Overweight rating on the shares. Arcalyst revenues came out on top, and management upped its 2024 guidance range by +8% at the midpoint, the firm notes. Wells thought further commentary on treatment duration and growth of prescribers sounded positive.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KNSA:
- Kiniksa Pharmaceuticals Reports Second Quarter 2024 Financial Results and Recent Portfolio Execution
- Kiniksa Pharmaceuticals Commences Enrollment in Abiprubart Phase 2b Clinical Trial in Sjögren’s Disease
- Kiniksa commence enrollment in Phase 2b trial of abiprubart
- Kiniksa files $400M mixed securities shelf
- Kiniksa, NHL Hall-of-Famer Henrik Lundqvist partner for pericarditis awareness
Questions or Comments about the article? Write to editor@tipranks.com